Literature DB >> 35918431

Role of Radioembolization in Metastatic Neuroendocrine Tumors.

Robert J Lewandowski1, Beau B Toskich2, Daniel B Brown3, Ghassan El-Haddad4, Siddharth A Padia5.   

Abstract

The liver is the most common site of metastasis for neuroendocrine tumors originating from the gastrointestinal tract. Neuroendocrine liver metastases (NELMs) portend a worsening clinical course, making local management important. Local treatment options include surgery, thermal ablation, and trans-catheter intra-arterial therapies, such as radioembolization. Radioembolization is generally preferred over other embolotherapies in patients with colonized biliary systems. Current best practice involves personalized treatment planning, optimizing tumor radiation absorbed dose and minimizing radiation to the normal hepatic parenchyma. As part of a multidisciplinary approach, radioembolization is a versatile embolotherapy offering neoadjuvant, palliative, and ablative treatment options for patients with NELMs.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Entities:  

Keywords:  Neuroendocrine liver metastases (NELMs); Radioembolization; Yttrium-90 (Y90)

Year:  2022        PMID: 35918431     DOI: 10.1007/s00270-022-03206-y

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.797


  62 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center.

Authors:  E T Janson; L Holmberg; M Stridsberg; B Eriksson; E Theodorsson; E Wilander; K Oberg
Journal:  Ann Oncol       Date:  1997-07       Impact factor: 32.976

3.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Pavel; K Öberg; M Falconi; E P Krenning; A Sundin; A Perren; A Berruti
Journal:  Ann Oncol       Date:  2020-04-06       Impact factor: 32.976

Review 4.  The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications.

Authors:  Mauro Cives; Eleonora Pelle'; Davide Quaresmini; Francesca Maria Rizzo; Marco Tucci; Franco Silvestris
Journal:  Neuroendocrinology       Date:  2019-01-30       Impact factor: 4.914

Review 5.  Therapeutic strategies for neuroendocrine liver metastases.

Authors:  Andrea Frilling; Ashley K Clift
Journal:  Cancer       Date:  2014-10-01       Impact factor: 6.860

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

8.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Authors:  James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

9.  Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.

Authors:  Charles W Kimbrough; Eliza W Beal; Mary E Dillhoff; Carl R Schmidt; Timothy M Pawlik; Alexandra G Lopez-Aguiar; George Poultsides; Eleftherios Makris; Flavio G Rocha; Angelena Crown; Daniel E Abbott; Alexander V Fisher; Ryan C Fields; Bradley A Krasnick; Kamran Idrees; Paula Marincola-Smith; Clifford S Cho; Megan Beems; Shishir K Maithel; Jordan M Cloyd
Journal:  Surgery       Date:  2018-10-28       Impact factor: 3.982

10.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.